PMC8841644_01
Timeline of the patient.
fmed-08-772998-g0001.jpg
PMC8841644_01_fmed-08-772998-g0001.jpg
F1
A 91-year-old male was admitted to the Department of Respiratory and Critical Care Medicine, Ruijin Hospital in October 2020 because of an incidental finding of a lung mass for 20 days, increased carcinoembryonic antigen (CEA) levels, and localized emphysema in a local hospital (Figure 1).
Positron emission tomography (PET)/MRI of the patient. (A) The high metabolic mass in the upper right lobe. (B) The high metabolic nodule at the apex of the right lung. (C) The small nodules in the upper right lobe with traction of the adjacent pleura, with slightly increased metabolism.
fmed-08-772998-g0002.jpg
PMC8841644_01_fmed-08-772998-g0002.jpg
F2
Positron emission tomography (PET):MRI of the chest revealed a highly metabolic mass in the upper right lobe, a highly metabolic nodule at the apex of the right lung, and small nodules in the upper right lobe with traction of the adjacent pleura, with a slightly increased metabolism (Figure 2).
Genetic analysis showing the Y1003S point mutation.
fmed-08-772998-g0003.jpg
PMC8841644_01_fmed-08-772998-g0003.jpg
F3
An MET Y1003S mutation was detected in the tissue (Figure 3) but not in the liquid biopsy.
Computed tomography (CT) scan of the primary lung lesion before and after crizotinib treatment. (A) In November 2020, the tumor size was 55 x 43 mm; (B) In January 2021, the tumor size was 26 x 17 mm; (C) In May 2021, the tumor size was 27 x 9 mm.
fmed-08-772998-g0004.jpg
PMC8841644_01_fmed-08-772998-g0004.jpg
F4
Chest CT scan on January 11, 2021 showed a partial response and significant improvement of the lung lesions (right upper lung: from 55 x 43 mm to 23 x 17 mm, Figure 4).